EuroBiotech: More Articles of Note


> French biotech Seekyo raised an €800,000 ($889,000) seed round. Seekyo will use the money to advance its lead chemotherapy ahead of a planned fundraising round to support clinical development. Release

> Otsuka Pharmaceutical entered into a drug discovery pact with PhoreMost. The partners plan to identify novel targets amenable to treatment with gene therapies. Statement 

> HepaRegeniX raised an €11 million ($12 million) series B round. The money will support the start of clinical tests of a MKK4 inhibitor developed for use in acute and chronic liver diseases. Release 


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> The FDA cleared Abivax to start a phase 2b trial of ABX464 in patients with moderate to severe ulcerative colitis. Enrollment is due to start in the second quarter. Statement 

> Autolus Therapeutics priced a public offering to raise around $80 million. Release 

Suggested Articles

One day after its Opdivo-paired prospect flopped, Five Prime is farming out some preclinical antibodies to keep its clinical-stage pipeline alive.

The deal will see GSK pay $50 million and commit to $550 million in milestones for TCRs against two solid tumor targets identified by Immatics. 

Gilead has a new head of research biology: Michael Quigley, Ph.D., an alum of MedImmune, Janssen and Dana Farber, who joins from Bristol-Myers Squibb.